For the quarter ending 2026-03-31, FLGT made $71,138K in revenue. -$24,826K in net income. Net profit margin of -34.90%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 71,138 | 83,336 | 84,069 | 81,803 |
| Cost of revenue | 49,648 | 50,754 | 48,557 | 47,368 |
| Gross profit | 21,490 | 32,582 | 35,512 | 34,435 |
| Research and development | 14,176 | 14,170 | 13,860 | 13,480 |
| Selling and marketing | 12,221 | 10,978 | 11,642 | 12,286 |
| General and administrative | 27,684 | 41,646 | 23,335 | 26,392 |
| Amortization of intangible assets | 2,031 | 2,026 | 2,025 | 1,990 |
| Total operating expenses | 56,112 | 68,820 | 50,862 | 54,148 |
| Operating loss | -34,622 | -36,238 | -15,350 | -19,713 |
| Interest income | 8,651 | 6,936 | 7,874 | 8,091 |
| Interest expense | 17 | 16 | 28 | 17 |
| Impairment gain | - | 0 | - | 9,926 |
| Other income (expense), net | 10 | 44 | -5 | 46 |
| Total other income, net | 8,644 | 6,964 | 7,841 | -1,806 |
| Loss before income taxes | -25,978 | -29,274 | -7,509 | -21,519 |
| (benefit from) provision for income taxes | -704 | -5,624 | -683 | -2,263 |
| Net loss from consolidated operations | -25,274 | -23,650 | -6,826 | -19,256 |
| Net loss attributable to noncontrolling interests | -448 | -232 | -218 | -299 |
| Net loss attributable to fulgent | -24,826 | -23,418 | -6,608 | -18,957 |
| Basic Average Shares | 30,881,000 | 30,983,000 | 30,749,000 | 30,544,000 |
| Diluted Average Shares | 30,881,000 | 30,983,000 | 30,749,000 | 30,544,000 |
Fulgent Genetics, Inc. (FLGT)
Fulgent Genetics, Inc. (FLGT)